GSTM1 and lymphoid neoplasm: In this study, in patients with lymphoid tumours, 52% of patients with a serum erythropoietin O/P ratio <0.9 achieved the expected response to therapy (Hb increase ⩾2 g dl−1), compared with 27% of patients with a baseline O/P ratio ⩾0.9.